Abstract LB039: Orally bioavailable BCL6 degrader HSK47977 featuring a novel CRBN ligand demonstrates potent antitumor activity and synergy with BCL2 inhibition in NHL
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Jun Xu, Qingyuan Meng, Yuting Liao, Chen Zhang, Jing Wei, Ruofeng Tang, Caixia Dou, Jie Yang, Pingming Tang, Zhen Chen, Yao Lu, Ju Wang, Pangke Yan
Institution: Haisco Pharmaceutical Group Co., Ltd. (China)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7154744003
Cites:
Cited by:
Related to: